Strategic Acquisition CoLucid was acquired by Eli Lilly in 2017 for approximately $960 million, indicating strong interest from major pharma players in migraine therapies and potential collaboration history that can inform future partnerships or licensing discussions.

Migraine Focus Lasmiditan targets acute migraine treatment with a novel mechanism (5-HT1F) and a vasoconstriction-free profile, presenting a compelling value proposition for health systems and payers seeking safer, rapid relief options for migraine patients.

ClinicalProof Seven completed clinical studies including a Phase 2b trial demonstrated efficacy in reducing moderate to severe headaches with favorable tolerability and no cardiovascular adverse signals, supporting conversations with clinical trial networks and KOLs.

CardioNiche Initial development targets migraine patients with cardiovascular risk factors or stable disease, creating a niche with potentially differentiated reimbursement and formulary considerations that can be leveraged in payer outreach.

FundingMomentum With prior funding totaling around $97 million and a lean employee base, opportunities exist to explore licensing, co-development, or strategic partnerships with larger pharma to scale manufacturing, distribution, and global clinical programs.